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Normalized periprostatic fat MRI 
measurements can predict prostate 
cancer aggressiveness in men 
undergoing radical prostatectomy 
for clinically localised disease
Naief Dahran1,2, Magdalena Szewczyk-Bieda1, Cheng Wei1, Sarah Vinnicombe1 &  
Ghulam Nabi1
Periprostatic and pelvic fat have been shown to influence prostate cancer behaviour through 
the secretion of chemokines and growth factors, acting in a paracrine mode. We have measured 
periprostatic fat volume (PFV) with normalisation to prostate gland volume on pelvic magnetic 
resonance imaging (MRI) and have correlated this with grade (Gleason score; GS) and pathological 
staging (pT) of prostate cancer (PCa) following radical prostatectomy (RP). PFV was determined using 
a segmentation technique on contiguous T1-weighted axial MRI slices from the level of the prostate 
base to the apex. The abdominal fat area (AFA) and subcutaneous fat thickness (SFT) were measured 
using T1-weighted axial slices at the level of the umbilicus and the upper border of the symphysis pubis, 
respectively. PFV was normalised to prostate volume (PV) to account for variations in PV (NPFV = PFV/
PV). Patients were stratified into three risk groups according to post-operative GS: ≤6, 7(3 + 4),  
and ≥7(4 + 3). NPFV was significantly different between the groups (p = 0.001) and positively 
correlated with post-operative GS (ρ = 0.294, p < 0.001). There was a difference in NPFV between those 
with upgrading of GS from 6 post prostatectomy (2.43 ± 0.98; n = 26) compared to those who continued 
to be low grade (1.99 ± 0.82; n = 17); however, this did not reach statistical significance (p = 0.11).
Several reports have found an association between obesity and aggressivity of prostate cancer (PCa) including 
an increased risk of biochemical recurrence following radical prostatectomy (RP)1–3. Most of these studies used 
body mass index (BMI) (kg/m2), which is a marker of generalised obesity. The calculation of BMI is based on the 
whole body weight and height. However, the BMI may not reflect the amount of metabolically active visceral and 
specifically, periprostatic and pelvic cavity fat. A number of factors, such as status of angiogenesis, adipogenesis, 
genetic regulation and insulin resistance determine the distribution of metabolically active fat in an individual4.
Periprostatic fat contains highly active adipocytes, which act as paracrine cells with the ability to secrete 
many growth factors, chemokines and inflammation-modifying molecules4, 5. Body fat is known to produce 
Interleukin-6 (IL-6), tumour necrosis factor-α (TNFα), leptin, and adiponectin, which have been shown to influ-
ence prostate cancer progression6–9. Free fatty acids (FFA), which are released from adipocytes closely spatially 
related to cancers are found to be the major source of energy for tumour cells in a number of cancers including 
prostate cancer10, 11.
There are several indications that periprostatic fat abundance can influence prostate cancer aggressiveness 
through paracrine effects12, 13. Inhibition of some of chemokine pathways, in particular CCR3/CCL7, prevents 
local dissemination of prostate cancer12. The CCR3/CCL7 chemokine pathway may promote extraprostatic exten-
sion of aggressive prostate cancers into periprostatic fat, and modification of the phenotype and characteristics of 
adipose cells occur which are then termed “cancer-associated adipocytes”12, 14.
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Measurement of periprostatic fat as a marker of prostate cancer aggressiveness has been reported using com-
puted tomography (CT) in men opting for prostate brachytherapy or external beam radiation, with conflicting 
results7, 8. Woo et al.15, in a retrospective review of MRI performed before radical prostatectomy (RP), showed a 
significant correlation between Gleason score (GS) of prostate cancer in prostatectomy specimen and peripros-
tatic fat thickness15. Similarly, Zhang et al.16, in 184 men undergoing RP found a positive correlation between 
periprostatic fat area and prostate cancer aggressiveness16. Both reports, however, used different methods of peri-
prostatic fat measurement. Woo et al. used the shortest perpendicular distance from pubic symphysis to prostate, 
whereas Zhang et al. measured periprostatic fat area, including ischiorectal fossae measurements. Also, a single 
transverse slice at the level of the femoral head and greater trochanter of the femur was used to give a measure of 
area instead of total volume. In a more recent study, Tan et al.17 found that periprostatic fat volume correlated with 
GS of prostate cancers on transrectal ultrasound guided biopsies17. This study did not use histopathology of RP 
as a reference standard and thus has limitations. Table 1 summarises various techniques, imaging modalities and 
methods used for estimations of periprostatic fat. Clearly, various reference standards and comparative measures 
have been used in the literature and this may have influenced the outcomes of these studies.
We hypothesised that normalisation of periprostatic fat volume to prostate size would provide a better 
reflection of relative fat volume in the pelvis and periprostatic area. The concept of normalisation is shown in 
Fig. 1. Therefore, the objectives of the present study were: 1. To measure periprostatic fat volume, subcutane-
ous fat thickness, and intra-abdominal fat area on anatomical MRI scans using a standardised measurement 
method. 2. To correlate fat measurements with grade (GS) and pathological staging (pT) of prostate cancer 
following RP.
Patients and Methods
Cohort Selection and Power Calculation. This is a prospective study with Caldicott institutional 
approval (Caldicott/CSAppGN021211). All experiments including the study protocol study followed approved 
institutional guidelines. The study had ethical approval (ethical approval number 13/ES/0099) with each par-
ticipant informed consenting to the use of their imaging data. A sample size of 150 was calculated based on 5% 
significance level with an effect size of 0.3 and 80% power. Allowing for 8% drop out for poor data quality, we 
planned recruitment of a cohort of 162 men. Between January 2010 and December 2015, 162 men with localised 
prostate cancer opting for RP were recruited. Prospective data were acquired for baseline demographic character-
istics, disease specific parameters and imaging including MRI of the prostate. Patient specific data were acquired 
through access to standard NHS online clinical databases. Study inclusion criteria were:
Study Reference standard Treatment Method Imaging modality Outcome
Woo et al.15 
Korea N = 190 Radical prostatectomy Surgery
Periprostatic and 
subcutaneous fat 
thicknesses.
Preoperative mid-sagittal T2W 
MRI. Measured the shortest 
perpendicular distance from 
symphysis pubis to skin and 
prostate.
Positive correlation 
between the 
periprostatic fat 
thickness and GS*
Roermund 
et al.7 
Netherlands 
N = 902
Prostate biopsies (? 
number) Brachytherapy
Periprostatic 
fat area (cm2)/
subcutaneous fat 
thickness (cm).
Two transverse 3 mm-thick CT 
slices at different levels. Pelvic 
fat was defined by the density 
range −190 to −30 HU*. Fat 
density (%) was calculated by 
dividing periprostatic fat area 
by total contour area.
Periprostatic fat 
area and density 
were not correlated 
with Prostate cancer 
aggressiveness
Roermund 
et al. (2010) 
Netherlands 
N = 932
Prostate biopsies (? 
number)
External 
radiotherapy and 
brachytherapy
Periprostatic 
fat area (cm2)/
Subcutaneous fat 
thickness.
Single transverse CT slice at the 
level of the femoral head and 
greater trochanter. Defined the 
pelvic fat by the density range 
−190 to −30 HU*. Fat density 
(%) was calculated by dividing 
periprostatic fat area by total 
contour area.
Higher periprostatic 
fat density had more 
often aggressive 
prostate cancer.
Bhindi et 
al.25 Canada 
N = 931
10–12 prostate biopsies unknown Periprostatic fat thickness.
Trans rectal ultrasonography 
(TRUS). The periprostatic 
fat was measured from the 
shortest perpendicular distance 
between pubic bone and 
prostate.
Periprostatic fat can 
be used as predictor 
for prostate cancer 
and high-grade 
prostate cancer at 
biopsy.
Tan et al.17 
USA N = 295 12 core prostate biopsies unknown
Periprostatic 
fat volume and 
prostate volume
3T MRIs. Periprostatic fat 
was marked from the level of 
its base to apex on T2W MR 
images ‘’cranial to caudal”. 
Ratio was calculated (fat 
volume/prostate volume)
Higher ratio may 
be a risk factor, 
is significantly 
associated with 
higher Gleason score
Zhang et al.16 
China N = 184 Radical prostatectomy Surgery
Periprostatic fat 
area (cm2) and 
Subcutaneous fat 
thickness
T2W transverse MRI slice at the 
level of the femoral head and 
greater trochanter of the femur.
Periprostatic fat can 
predict the prognosis 
of patient with 
radical retropubic 
prostatectomy.
Table 1. Periprostatic fat measurement techniques on imaging and their outcomes in previous studies. 
*GS = Gleason score. *HU = Hounsfield unit.
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•	 Men with localised prostate cancer without prior radiotherapy or hormonal treatment.
•	 Radical prostatectomy as a treatment option.
•	 Gleason score and histopathological stage of RP specimens review by an experienced uropathologist and MRI 
review by uroradiologists.
Exclusion criteria were: men with metastatic prostate cancer or those with localised prostate cancer opting for 
external beam radiotherapy or brachytherapy.
Imaging Protocol. MRI scans were acquired using either 3-T (n = 65) or 1.5-T (n = 97) Siemens 
MR units with pelvic phased array coils. All patients received 20 mg of butyl scopolamine (Buscopan; 
Boehringer-Ingelheim) injected intramuscularly before MRI to minimize peristalsis.
Axial, sagittal and coronal T2-weighted spin-echo sequences, axial T1-weighted spin-echo sequences and 
axial fat-suppressed single-shot echo-planar diffusion weighted imaging using a small field of view (SFV) of the 
pelvis were routinely obtained for all patients, according to the standard prostate cancer characterisation MRI 
protocol in use at the time. Dynamic contrast-enhanced imaging was performed on a subgroup of patients under-
going imaging at 3 T unit as part of the standard multiparametric prostate MRI protocol at our institution. The 
data obtained form a part of the ongoing MULTIPROS study (http://www.hra.nhs.uk/news/research-summaries/
multipros-study/). Table 2 summarises the imaging protocol of all sequences used in this study.
Fat Measurements. After anonymization of MRI studies from 162 men who subsequently underwent RP 
for clinically non-metastatic disease, the PFV was determined by using a semi-automated segmentation tech-
nique on contiguous 3 mm T1-weighted axial slices. OsiriX MD © Pixmeo Sarl 2015 (http://www.osirix-viewer.
com) software was used for these measurements. The software utilises bicubic interpolation to deal with interslice 
Figure 1. Schematic diagram explaining the concept of Normalised Periprostatic Fat Volume.
TR/TE (ms)
Slice 
thickness 
(mm)
Interslice 
gap (mm) Matrix
FoV 
read 
(mm)
Parallel 
imaging 
acceleration 
factor
1.5 Tesla MRI
T1W
Axial pelvic 650/11 3 0.6 320 × 320 200 2
Trans. Pelvic LN 532/9.4 6 0.6 320 × 240 380 2
Trans. Abdomen 166/4.76 6 0.6 256 × 192 380 2
T2W Axial pelvic 3,890/100 3 0.6 512 × 512 200 2
3.0 Tesla MRI
T1W
Axial pelvic 650/12 3 0.6 320 × 320 200 2
Trans. Pelvic LN 755/13 6 0.6 320 × 240 280 4
Trans. Abdomen 140/2.46 5 0.6 320 × 250 380 2
T2W Axial pelvic 4,000/95 3 0.6 320 × 320 280 2
Table 2. Imaging protocol.
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gaps (in this study, 0.6 mm for both T1 and T2-weighted sequences). It was established that segmentation was most 
accurate and reproducible on non fat suppressed T1-weighted images, which provided optimal contrast between 
adipose and all other non-adipose tissues. One observer carried out all segmentations and measurements, blinded 
to GS and postoperative T stage.
The periprostatic fat was segmented from the level of the prostate base to the apex (Figs 2 and 3). The subcu-
taneous fat thickness (SFT) was determined by measuring the perpendicular distance between the skin and the 
anterior upper border of the symphysis pubis on a selected T1-weighted small field of view axial slice (Fig. 4). The 
abdominal fat area (AFA) was determined by segmenting the intra-abdominal fat on a single T1-weighted axial 
slice at the level of umbilicus including retroperitoneal fat (Fig. 5). Prostate volume (PV) was measured from 
multiple contiguous T2-weighted SFV axial images (Fig. 6). Since the dimensions of the prostate gland including 
the distance between apex and base are highly variable between individuals, PFV was normalised for all patients 
Figure 2. Sagittal and coronal images were used to identify the first slice at the level of the base of the 
prostate represented by the green lines. The yellow area represents the periprostatic fat, which was segmented 
from multiple sequential slices starting from this level to the prostate apex. P = Prostate gland; B = Bladder; 
R = Rectum; SV = Seminal Vesicle.
Figure 3. Segmentation technique to measure the volume of periprostatic fat (masked in yellow) from multiple 
sequential slices of axial T1 weighted MRIs. P = Prostate; B = Bladder; OI = Obturator internus muscle; 
R = Rectum; I = Ischiorectal fossa.
www.nature.com/scientificreports/
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Figure 4. Measurement of subcutaneous fat thickness from the perpendicular distance between symphysis 
pubis and skin at the level of the superior pubic ramus on T1 weighted transverse pelvis MRI. P = Prostate gland; 
R = Rectum; S = Symphysis pubis; SF = Subcutaneous fat.
Figure 5. Abdominal fat area (masked in yellow) was measured from T1 weighted transverse abdominal 
MRI at the level of umbilicus using segmentation technique. L = Lumbar vertebral body; P = Psoas muscle; 
SF = Subcutaneous fat; U = Umbilicus; W = Abdominal wall muscles.
Figure 6. Prostate volume was measured from T2 weighted axial sequential images. The region of interest was 
marked manually from each slice using pencil starting from the level of the base of the prostate till the level 
of its apex. Subsequently the software automatically calculates the volume. P = Prostate gland; R = Rectum; 
I = Ischiorectal fossa; SP = Symphysis pubis.
www.nature.com/scientificreports/
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to account for the variations in PV (NPFV = PFV/PV). NPFV is the normalised value of periprostatic fat volume 
measured from the base of the prostate to its apex.
Reproducibility of PFV and PV measurements was assessed in a subgroup of 10 randomly selected study 
patients by three observers. An excellent interrater reliability was shown with intraclass correlation coefficient of 
0.984 in single measures (P < 0.001).
Statistical Analyses. Patients were stratified into three groups according to the Gleason score of the final 
prostatectomy specimen: ≤6, 7(3 + 4) and 7(4 + 3) or more. The association between the three groups and dif-
ferent fat measurements including clinical and pathological data was determined using one-way ANOVA and 
Kruskal-Wallis tests for parametric and non-parametric continuous variables, respectively, and Chi-square test 
for categorical variables (WHO weight classification, pT and D’Amico risk classification). Receiver Operating 
Characteristic (ROC) curve analysis was used to test the ability of NPFV to differentiate between high-grade 
(GS ≥ 7) and low-grade (GS ≤ 6) prostate cancers.
Pearson correlation coefficient was used to evaluate the relationship between the different fat measurements 
(NPFV, AFA and SFT), including BMI, and prostate cancer aggressiveness [GS: ≤6, 7 (3 + 4), 7 (4 + 3), 8 and 9, 
pT: pT2 and pT3]. After classifying the patients based on D’Amico risk classification, binary logistic regression 
analysis was used to determine an independent effect of each predictor on high-risk disease (biopsy GS ≥ 8 or 
PSA > 20, more than one positive core, or intermediate-risk and more than 50% positive cores) vs non-high risk 
(low and intermediate-risk) disease. p value of <0.05 was considered statistically significant. IBM SPSS Statistics 
(version 23) for OS X was used for data analyses.
Results
The mean age of the cohort (N = 162) was 67.3 ± 5.7 years (range, 53–87), and the mean BMI was 27.6 ± 4 kg/m2 
(range, 20.5–40.6). According to the WHO classification, 47 patients were classified as normal weight (30.1%), 70 
as overweight (44.9%) and 39 as obese (25%). Table 3 summarizes the characteristics of patients categorised into 
three groups according to post-operative Gleason score of histopathology.
The mean age was statistically different between the three groups [F (2,159) = 3.9, p = 0.022], patients with 
more aggressive disease tending to be older. The mean NPFV was also statistically different between the groups 
[F (2,159) = 7, p = 0.001], and Tukey post-hoc test revealed that NPFV was statistically significantly larger in 
Group 2 (2.45 ± 1.13, p = 0.047) and Group 3 (2.79 ± 1.15, p = 0.001) than in Group 1 (1.84 ± 0.76). There was no 
Group 1 6 Group 2 Group 3
p value
Post-operative 
Gleason score ≤
Post-operative 
Gleason score 7 
(3 + 4)
Post-operative 
Gleason score 7 (4 + 3) 
and over
Mean ± Standard Deviation
 No. n = 25 n = 71 n = 66
 Age (years) 65.72 ± 6.07 66.45 ± 5.82 68.70 ± 5.07 0.022a
 NPFV (cm3) 1.84 ± 0.76 2.45 ± 1.13 2.8 ± 1.56 0.001a
 AFA (cm2) 137.51 ± 65.12 126.12 ± 50.75 144.42 ± 61.27 0.177a
 SFT (cm) 3.84 ± 1.56 3.7 ± 1.18 3.8 ± 1.34 0.853a
 BMI (kg/m2) 27.87 ± 4.69 27.31 ± 3.61 27.73 ± 4.28 0.781a
 Initial PSA (ng/ml) 9.86 ± 5.29 11.06 ± 5.71 15.21 ± 11.11 0.006b
 PV (cm3) 63.29 ± 26.99 54.71 ± 32.07 51.01 ± 19.94 0.051b
WHO classification N (%)*
 No. n = 23 n = 69 n = 64
0.946c
 Normal weight 7 (30.4) 22 (31.9) 18 (28.1)
 Overweight 9 (39.1) 31 (44.9) 30 (46.9)
 Obesity 7 (30.4) 16 (23.2) 16 (25)
Pathological stage N (%)*
 No. n = 25 n = 71 n = 66
0.001c T2 20 (80) 43 (60.6) 25 (37.9)
 T3 5 (20) 28 (39.4) 41 (62.1)
D’Amico risk classification N (%)*
 No. n = 25 n = 71 n = 66
<0.001c
 Low 18 (72) 18 (25.4) 2 (3)
 Intermediate 6 (24) 40 (56.3) 27 (40.9)
 High 1 (4) 13 (18.3) 37 (56.1)
Table 3. Patient characteristics. NPFV = Normalised periprostatic fat volume; AFA = Abdominal fat area; 
SFT = Subcutaneous fat thickness; BMI = Body mass index; PSA = Prostate specific antigen; PV = Prostate 
volume. Patients were stratified according to post-operative Gleason score. aANOVA, bKruskal-Wallis test, cχ2 
test. *(%) within each group. P value is significant <0.05.
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statistically significant difference between Group 2 and Group 3 (p = 0.156). Patients with stage pT2 had statisti-
cally significantly lower NPFV (2.28 ± 0.98) than patients with stage pT3 (2.76 ± 1.25), t(160) = −2.760, p = 0.006.
Dichotomising PCa into low (GS ≤ 6) and high (GS ≥ 7) grade groups, ROC curve analysis yielded an area 
under the curve of 0.71, with Youden’s Index of 1.81 for a sensitivity of 73.7% and specificity 60% (p ≤ 0.001).
The NPFV was significantly correlated with post-operative GS (ρ = 0.294, p < 0.001). BMI was significantly 
positively correlated with AFA (ρ = 0.640, p < 0.001) and SFT (ρ = 0.794, p < 0.001). PSA was correlated with 
AFA (ρ = 0.207, p = 0.008) and SFT (ρ = 0.162, p = 0.039) but not to BMI (ρ = 0.121, p = 0.132) (Table 4). Neither 
BMI, AFA nor SFT correlated with post-operative GS (Table 4), nor was there any relationship with pathological 
stage (pT2 and pT3), [t (160) = 0.430, p = 0.668], [t(160) = 0.305, p = 0.760] and [t(154) = 0.492, p = 0.43], respec-
tively. Twenty-six men had upgradation of GS from 6 to 7 and above from TRUS biopsy to final histopathology 
of the radical prostatectomy specimen. Mean NPFV of these men (2.43 ± 0.98) was more than those who had no 
upgrade from GS 6 (n = 17; 1.99 ± 0.82). This did not reach statistically significance, however, due to low numbers 
(p = 0.132).
Binary logistic regression analysis showed that NPFV was the only independent predictor of having high-risk 
PCa after controlling for age (OR, 1.398; 95% CI, 1.037–1.883; p = 0.028). Age was not an independent predictor 
of having high-risk PCa (OR, 0.969; 95% CI, 0.911–1.03; p = 0.313). Hosmer-Lemeshow test revealed that the 
data fitted the model well [χ2(8) = 5.273, p = 0.728].
Discussion
This is the first prospective study that reports on the periprostatic and pelvic fat volume measured from contig-
uous T1-weighted axial images using a semi-automated segmentation technique, showing a strong correlation 
between prostate post-operative Gleason score and normalised periprostatic fat volume. In contrast to other 
studies conducted in the America and Canada1–3, 18, our observations show that periprostatic fat correlates better 
with GS than BMI, the marker of general obesity, which had no relation to PCa aggressiveness (as defined by GS) 
in this study. Our findings are, however in agreement with other reports from Europe suggesting no association 
between BMI and risk of being diagnosed with more aggressive prostate cancer8, 19. The discrepancy between the 
results needs further exploration, yet it could reflect differences in the percentage of the adult population who 
are clinically obese, which is higher in North America, and may be affected by the greater proportion of African 
Americans who tend to have more aggressive disease compared to Caucasian Americans20–24.
Recent studies have confirmed the relationship between periprostatic fat and PCa aggressiveness using dif-
ferent measurement techniques on trans-rectal ultrasonography (TRUS), CT and MRI8, 15, 16, 25. There are several 
differences between the previous studies and our study. Firstly, we measured periprostatic fat volume using a 
dedicated software rather than thickness of fat or area at a single point. Secondly, we have used RP as a reference 
standard, as it is established that there is a discrepancy between histological grade obtained during biopsies and 
final histopathology of prostatectomy specimen after radical surgery26, and confirmed in the results presented in 
this study.
Correlations
NPFV AFA SFT PSA BMI Biopsy GS Post-op GS
Age
Pearson C. 0.154 0.046 −0.090 0.061 −0.149 0.133 0.147
Sig. (2-tailed) 0.050 0.561 0.256 0.444 0.064 0.092 0.062
N 162 162 162 162 156 162 162
NPFV
Pearson C. 1 0.129 0.042 0.036 0.117 0.331** 0.294**
Sig. (2-tailed) 0.101 0.596 0.645 0.146 0.000 0.000
N 162 162 162 162 156 162 162
AFA
Pearson C. 0.129 1 0.644** 0.207** 0.640** 0.098 0.046
Sig. (2-tailed) 0.101 0.000 0.008 0.000 0.213 0.563
N 162 162 162 162 156 162 162
SFT
Pearson C. 0.042 0.644** 1 0.162* 0.794** 0.062 −0.004
Sig. (2-tailed) 0.596 0.000 0.039 0.000 0.435 0.960
N 162 162 162 162 156 162 162
PSA
Pearson C. 0.036 0.207** 0.162* 1 0.121 0.169* 0.326**
Sig. (2-tailed) 0.645 0.008 0.039 0.132 0.031 0.000
N 162 162 162 162 156 162 162
BMI
Pearson C. 0.117 0.640** 0.794** 0.121 1 0.079 0.020
Sig. (2-tailed) 0.146 0.000 0.000 0.132 0.326 0.800
N 156 156 156 156 156 156 156
Table 4. The relationship between post RP Gleason score, age, body mass index (BMI), prostate-specific 
antigen (PSA) and different fat measurements using Pearson correlation coefficient. *Correlation is significant 
at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed). NPFV = Normalised 
periprostatic fat volume; AFA = Abdominal fat area; SFT = Subcutaneous fat thickness; PSA = Prostate specific 
antigen; BMI = Body mass index; GS = Gleason score.
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Van Roermund et al.8 evaluated periprostatic fat as a predictive marker for prostate cancer aggressiveness 
using a single 3 mm-thick CT slice8. They showed that the periprostatic fat area and density (defined as peri-
prostatic fat area/total contour area) (%), were predictors for cancer aggressiveness. Woo et al.15 reported that 
there was a positive correlation between periprostatic fat thickness, which was measured on a single preoper-
ative mid-sagittal T1-w MRI from the symphysis pubis to the prostate, and GS15. Body fat distribution differs 
between individuals according to differences in age, angiogenesis, adipogenesis, genetic regulation and insulin 
resistance27–29. Moreover, since the prostate tumour and cancer-related adipocytes can be located at any level in 
the gland (most commonly in the posteriorly located peripheral zone), we considered that measuring the volume 
of periprostatic fat from the level of the prostate base to its apex was most appropriate.
There are several reports on the correlation between peritumoural fat and cancer outcomes. It has been sug-
gested that retroperitoneal fat should be included in visceral fat measures as leptin, which promotes PCa pro-
gression, and adiponectin were associated with retroperitoneal fat area30, 31. Ohwaki et al.32 suggested that BMI 
is not an accurate marker for abdominal obesity assessment, and that the visceral (intraperitoneal) fat is the 
most accurate measurement for abdominal obesity32. Van Roermund et al.7 also concluded that the visceral fat 
could be more metabolically active than periprostatic fat after observing the relationship between BMI, SFT and 
periprostatic fat density7. Harada et al.33 measured the abdominal fat area at the level of umbilicus on 507 CT 
images, and concluded that low visceral fat contents were associated with poor prognosis in patients with upper 
gastrointestinal cancers33. In the present study, we measured AFA from a T1-weighted axial image at the level of 
the umbilicus including retroperitoneal fat. AFA and SFT were significantly positively correlated with BMI but 
not related to grade and stage of prostate cancer. Visceral fat, unlike periprostatic fat, could be related to upper 
gastrointestinal cancers but not to prostate cancer. This suggests that a close spatial relationship between a cancer 
and its peritumoural fat tissue is important in consideration of aggressivity and outcomes.
In this study, NPFV was positively correlated with both grade and stage of prostate cancer. A previous study 
showed that the adipocytes spatially related to a cancer release free fatty acids through lipolysis which are then 
used by the cancer cells for bioenergy11. Mitochondrial β-oxidation of the free fatty acids was found to be the 
dominant source of bioenergy for PCa cells10. This may indicate that both fat amount and activity have an impact 
on prostate cancer progression.
Anatomical MRI scans cannot distinguish between less or more active adipocytes of periprostatic fat tis-
sue. Powell34 reported that there are two types of adipocytes, “fat” and “thin”34. The activated “fat” adipocytes 
are common in obese patients and produce more adipokines than “thin” adipocytes34. A few laboratory studies 
have concluded that there is a relationship between active periprostatic adipose tissue and prostate cancer cell 
survival, migration and higher risk of biochemical recurrence10, 35. Finley et al.36 investigated the association of 
adipose tissue cytokines with PCa aggressiveness36. IL-6 levels of both serum and periprostatic adipose tissue 
were compared with Gleason score (GS). The results showed that IL-6 secreted by periprostatic adipose tissue 
was approximately 375-fold greater than serum IL-6, and positively correlated with GS. They also mentioned 
that adipocytes of periprostatic fat tissue are the major secretors of IL-6 in patients with PCa. For future studies, 
it could be informative to further investigate both periprostatic fat adiposity and metabolic activity as the results 
may better reveal the relationship between the active periprostatic fat and PCa aggressiveness.
This study has some limitations. The slice-by-slice semi-automated segmentation technique was time con-
suming. Though the Osirix software factors in any interslice gap into volumetric calculations, a 3D volumetric 
acquisition with no interslice gap might allow more accurate segmentation. However, the theoretical impact of 
this on our results is likely to be minimal, since the same sequences were used in all subjects and slice thickness 
and gap were the same for the T1 and T2-weighted sequences used for determination of NPFV and PV, respec-
tively. Furthermore, the segmentation technique showed excellent reproducibility. Though Dixon sequences are 
regarded as the gold standard in the determination of fat and water volumes, some form of user-defined thresh-
olding is still necessary with semi-automated softwares. It could be argued that the sequences routinely used in 
2010 when recruitment to this study commenced would not be regarded as ideal for multiparametric MRI char-
acterisation of PCa according to PI-RADS v. 2 criteria. However, this will not have affected the research question 
addressed here; namely, the relationship of NPFV to PCa aggressivity.
A further limitation is that our inclusion criteria, using radical prostatectomy Gleason score as a reference 
standard, has restricted our cohort to 162 patients over a long period of time (2010–2015). Using this strict refer-
ence standard may limit the external validity of findings from the present study and introduce a selection bias, as 
patients with low Gleason score disease may not opt for radical surgery and may instead go onto active surveil-
lance as a treatment choice. In the present study, there was a higher NPFV in men with upgradation of disease 
from Gleason 6 score on biopsy to GS > 6 following radical prostatectomy compared to those who continued to 
have low GS disease. The discriminatory power of NPFV in this clinical situation needs further study due to low 
number of cases. Even accepting the low numbers, we have demonstrated with ROC analysis that NPFV is clearly 
able to differentiate between high- and low-risk disease suggesting that it could be used to stratify patients into 
differing treatment groups. Observation from the present study and previous reports, however, do merit future 
research in selecting men for active surveillance using periprostatic fat volume as marker of aggressive disease, 
particularly in those where there is suspicion of poor sampling using ultrasound guided biopsies.
Conclusions
In the present study, normalised periprostatic fat volume measured from MRI images significantly correlated 
with prostate cancer aggressiveness (grade and stage) in men who underwent radical prostatectomy for clinically 
non-metastatic disease. There was no correlation between BMI, AFA and SFT and prostate cancer aggressiveness. 
Defining the metabolic activity of periprostatic fat could add further to understanding the relationship between 
the active closely-related adipose tissue and PCa aggressiveness.
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 4630  | DOI:10.1038/s41598-017-04951-8
References
 1. Amling, C. L. et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing 
radical prostatectomy. J. Clin. Oncol. 22, 439–445 (2004).
 2. Palma, D., Pickles, T. & Tyldesley, S. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for 
prostate cancer. BJU Int. 100, 315–319 (2007).
 3. Rodriguez, C. et al. Body mass index, weight change, and risk of prostate cancer in the cancer prevention study ii nutrition cohort. 
Cancer Epidemiol. Biomarkers Prev. 16, 63–9 (2007).
 4. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 518, 187–196 (2015).
 5. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85–97 
(2011).
 6. Van Roermund, J. G. & Witjes, J. A. The impact of obesity on prostate cancer. Wourld J. Urol. 25, 491–497 (2007).
 7. Van Roermund, J. G. et al. Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness. 
World J. Urol. 28, 699–704 (2009).
 8. Van Roermund, J. G. et al. Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients. BJU Int 107, 1775–1779 
(2011).
 9. Von Hafe, P., Pina, F., Perez, A., Tavares, M. & Barros, H. Visceral fat accumulation as a risk factor for prostate cancer. Obes. Res. 12, 
1930–1935 (2004).
 10. Liu, Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 9, 230–234 (2006).
 11. Nieman., K. M., Romero, I. L., Lengyel, E. & Van Houten, B. Adipose tissue and adipocytes support tumorigenesis and metastasis. 
Biochim. Biophys. Acta. 1831, 1533–1541 (2013).
 12. Laurent, V. et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat. Commun. 7, 10230 
(2016).
 13. Taylor, R. A., Lo, J., Ascui, N. & Watt, M. J. Linking obesogenic dysregulation to prostate cancer progression. Endocr. Connect 4, 
R68–R80 (2015).
 14. Muller, C. Tumour-surrounding adipocytes are active players in breast cancer progression. Ann. Endocrinol. 74, 108–110 (2013).
 15. Woo, S., Cho, J. Y., Kim, S. Y. & Kim, S. H. Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer. AJR 
Am. J. Roentgenol. 204, W43–W47 (2015).
 16. Zhang, Q. et al. Periprostatic adiposity measured on magnetic resonance imaging correlates with prostate cancer aggressiveness. 
Urol. J. 11, 1793–1799 (2014).
 17. Tan, W. P., Lin, C., Chen, M. & Deane, L. A. Periprostatic fat: a risk factor for prostate cancer? Urology doi:10.1016/j.
urology.2016.07.042 (2016).
 18. Freedland, S. J., Terris, M. K., Platz, E. A. & Presti, J. C. Jr. Body mass index as a predictor of prostate cancer: development versus 
detection on biopsy. Urology. 66, 108–113 (2005).
 19. Paaskesen, C. E. & Borre, M. Body mass index and prognostic markers at radical prostatectomy. Scand. J. Urol. Nephrol. 42, 230–236 
(2008).
 20. Keaver, L. et al. Application of the UK foresight obesity model in Ireland: the health and economic consequences of projected obesity 
trends in Ireland. PLoS One. 8, e79827 (2013).
 21. Shields, M., Carroll, M. D. & Ogden, Cl Adult obesity prevalence in Canada and the United States. Nchs Data Brief. 2, 368–369 
(2011).
 22. Ogden, C. L. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 295, 1549–1555 (2006).
 23. Powell, I. J., Bock, C. H., Ruterbusch, J. J. & Sakr, W. Evidence supports a faster growth rate and/or earlier transformation to clinically 
significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J. Urol. 
183, 1792–1796 (2010).
 24. Rennie, K. & Jebb, S. A. Prevalence of obesity in Great Britain. Obes. Rev. 6, 11–12 (2005).
 25. Bhindi, B. et al. Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate 
cancer. BJU Int. 110, 980–986 (2012).
 26. Cohen, M. S. et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical 
Center experience and an international meta-analysis. Eur. Urol. 54, 371–381 (2008).
 27. Wang, Y. Y. et al. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. Cancer Lett. 324, 142–151 
(2012).
 28. Tordjman, J. Physiology and Pathophysiology of Adipose Tissue (Bastard, J. P. & Feve, B.), 67 (Springer, 2013).
 29. Rutkowski, J. M., Davis, K. E. & Scherer, P. E. Mechanisms of obesity and related pathologies: the macro- and microcirculation of 
adipose tissue. FEBS J. 276, 5738–5746 (2009).
 30. Hung, C. S. et al. Measurement of visceral fat: should we include retroperitoneal fat? PloS One. 9, e112355 (2014).
 31. Saglam, K., Aydur, E., Yilmaz, M. & Goktas, S. Leptin influences cellular differentiation and progression in prostate cancer. J. Urol. 
169, 1308–1311 (2003).
 32. Ohwaki, K., Endo, F. & Hattori, K. Abdominal obesity, hypertension, antihypertensive medication use and biochemical recurrence 
of prostate cancer after radical prostatectomy. Eur. J. Cancer. 51, 604–609 (2015).
 33. Harada, K. et al. Low visceral fat content is associated with poor prognosis in a database of 507 upper gastrointestinal cancers. Ann. 
Surg. Oncol. 22, 3946–3953 (2015).
 34. Powell, K. Obesity: the two faces of fat. Nature. 447, 525–527 (2007).
 35. Ribeiro, R. et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J. Exp. Clin. Cancer Res. 31, 
1–11 (2012).
 36. Finley, D. S. et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J. Urol. 182, 1621–1627 (2009).
Author Contributions
N.D. has been a PhD student and been responsible for collecting data, analyses and preparing first draft. M.S. has 
been responsible for radiological data supervision and critical scientific input, C.W. has been responsible for mold 
and 3D printing data and has significant input into the final version of the manuscript. A.A. has been contributed 
in the interrater reliability measures of the first 10 patients. S.V. has been responsible for supervision of the study, 
critical input into radiological data and final manuscript of the study. G.N. is overall responsible for the study 
including its concept, supervision, preparation of manuscript and critical intellectual input of the final version.
Additional Information
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 4630  | DOI:10.1038/s41598-017-04951-8
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
